Atypical antipsychotics in the managed care era

American Journal of Managed Care

Volumn 4, Issue 1 SUPPL., 1998, Pages

  Loebel, Antony D ^a,c   Botts, Sheila R ^b   Feldman, Beth I ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b ST JOHN'S UNIVERSITY   (United States)

^c Hillside Hospital

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

COST EFFECTIVENESS ANALYSIS; DRUG USE; ECONOMIC ASPECT; HUMAN; MANAGED CARE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; TREATMENT INDICATION;

EID: 0031875051     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. DiMasi JA, Lasagna L. The economics of psychotropic drug development. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generations of Progress. New York, NY: Raven Press 1995:1883-1895.
2. Rupp A, Keith SJ. The costs of schizophrenia: Assessing the burden. Psychiatr Clin North Am 1993;16:413-423.
3. Meltzer HY, Cola PA. The pharmacoeconomics of clozapine: A review. J Clin Psychiatry 1994;55(9 Suppl B):161-165.
4. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophren Bulletin 1995; 21:419-429.
5. Carpenter WT, Buchanan RW. Schizophrenia. N Engl J Med 1994;330:681-690.
6. Lieberman JA, Koreen AR, Chakos M, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: Implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry 1996;57(Suppl.9):5-9.
7. Dixon LB, Lehman AF, Levine J. Conventional antipsychotic medications for schizophrenia. Schizophren Bulletin 1995;21: 567-577.
8. Cassens G, Inglis AK, Appelbaum PS, Gutheil TG. Neuroleptics: Effects on neuropsychological function in chronic schizophrenic patients. Schizophren Bulletin 1990;16:477-499.
9. Carpenter WT. The treatment of negative symptoms: Pharmacological and methodological issues. Br J of Psych 1996;168(Suppl 29):17-22.
10. Hansen TE, Casey DE, Hoffman WF. Neuroleptic intolerance. Schizophren Bulletin 1997;23:567-582.
11. Miller R. Dose response relationships for the antipsychotic effects and parkinsonian side-effects of typical neuroleptic drugs: Practical and theoretical implications. Prog Neuropsychopharmacol Biol Psychiatry 1997;21:1059-1094.
12. Meltzer HY. Pre-clinical pharmacology of atypical antipsychotic drugs: A selective review. Br J Psychiatry 1996;168(Suppl 29):23-31.
13. Lieberman JA. Understanding the mechanism of action of atypical antipsychotic drugs: A review of compounds in use and development. Br J Psychiatry 1993;163 (Suppl 22):7-18.
14. Reynolds GP. What is an atypical anti-psychotic? J of Psychopharmacology 1997; 11:195-199.
15. Kane JM. What makes an antipsychotic "atypical"? Should the definition be preserved? CNS Drugs 1997;7:347-348.
16. Meltzer HY. The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics. J Clin Psychopharmacology 1995;15(Suppl 1):25-35.
17. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996; 153: 366-476.
18. Borison RL. Recent advances in the pharmacotherapy of schizophrenia. Harvard Rev Psychiatry 1997;4:255-271.
19. Keck PE, McElroy SL. The new antipsychotics and their therapeutic potential. Psychiatric Annals 1997;5:320-331.
20. Kane JM, Honigfeld G, Singer J, Meltzer HY for the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796.
21. Umbricht D, Kane JM. Risperidone: Efficacy and safety. Schizophren Bulletin 1995;21:593-606.
22. Mattes JA. Risperidone: How good is the evidence for efficacy? Schizophren Bulletin 1997;23:155-161.
23. Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am J Psychiatry 1997;154:457-465.
24. Arvanitis LA, Miller BG and the Seroquel Trial 13 Study Group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-246.
25. Packer S, Husted J, Cohen S, Tomlinson G. Psychopathology and quality of life in schizophrenia. J Psychiatric Neurosci 1997;22:231-234.
26. Carpenter WT, Heinrich DW, Wagman AM. Deficit and non-deficit forms of schizophrenia: The concept. Am J Psychiatry 1988;145:578-583.
27. Buchanan RW. Clozapine: Efficacy and safety. Schizophren Bulletin 1995;21:579-591.
28. Carpenter WT. Serotonin-dopamine antagonists and treatment of negative symptoms. J Clin Psychopharmacol 1995;15 (Suppl 1):30S-35S.
29. Möller HJ. The negative component in schizophrenia. Acta Psychiatry Scand 1995;91(Suppl 388):11-14.
30. Tollefson GD, Sanger TM. Negative symptoms: A path analytic approach to a double-blind placebo and haloperidol controlled clinical trial with olanzapine. Am J Psychiatry 1997;154:466-474.
31. Schooler NR, Keith SJ, Severe JB, et al. Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Arch Gen Psychiatry 1997;54: 453-463.
32. Meltzer HY. Dimensions of outcome with clozapine. Br J Psych 1992;160(Suppl 17):46-53.
33. Marder SR. Management of treatment-resistant patients with schizophrenia. J Clin Psychiatry 1996;57(Suppl.11):26-30.
34. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154(Suppl):3.
35. Kane JM. Schizophrenia N Engl J Med 1996;334:34-41.
36. Green AI, Schildkraut JJ. Should clozapine be a first-line treatment for schizophrenia? The rationale for a double-blind clinical trial in first-episode patients. Harvard Rev Psychiatry 1995;3:1-9.
37. Hoff AL. Neuropsychological function in schizophrenia. In: Shriqui CL, Nasrallah HA eds. Contemporary Issues in the Treatment of Schizophrenia. 1st Edition. American Psychiatric Press, Inc.;1995:187-208.
38. Andreasen NC. Linking mind and brain in the study of mental illnesses: A project for a scientific psychopathology. Science 1997;275:1586-1593.
39. Stip E. Memory impairment in schizophrenia: Perspectives from psychopathology and pharmacotherapy. Can J Psychiatry 1996;41(Suppl 2):275-345.
40. Lee MA, Thompson PA, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry 1994;55 (Suppl B):82-87.
41. Gallhofer B, Bauer U, Liss, et al. Cognitive dysfunction in schizophrenia: Comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol 1996;6:52-13-52-20.
42. Simpson GM, Lindenmayer JP. Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacology 1997;17:194-201.
43. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418.
44. Egan MF, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schizophren Bulletin 1997;23:583-609.
45. Chouinard G. Effects of risperidone in tardive dyskinesia: An analysis of the Canadian Multicenter Risperidone Study. J Clin Psychopharmacol 1995;15(Suppl 1):36-44.
46. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophren Bull 1991;17:325-351.
47. Lieberman JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: A rationale and hypothesis. J Clin Psychiatry 1996;57(Suppl 11):68-71.
48. Lehman A, Ward J, Linn L. Chronic mental patients: The quality of life issues. Am J Psychiatry 1982;139:1271-1276.
49. Awad AG, Hogan TP. Subjective response to neuroleptics and the quality of life: Implication for treatment outcome. Acta Psychiatry Scand 1994;89(Suppl 380): 27-32.
50. Weiden PJ, Mott T, Cureio N. Recognition and management of neuroleptic non-compliance. In: Shriqui CL, Nasrallah HA eds. Contemporary Issues in the Treatment of Schizophrenia. 1st Edition. American Psychiatric Press, Inc.; 1995:411-434.
51. Fulton B, Goa KL. Olanzapine: A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 1997;53:281-298.
52. Franz M. Lis S, Pluddemann, Gallhofer B. Conventional versus atypical neuroleptics: Subject quality of life in schizophrenic patients. Br J Psychiatry 1997;170:422-425.
53. Breier A, Buchanan R, Irish D, et al. Clozapine treatment of outpatients with schizophrenia: Outcome and long-term response patterns. Hosp Community Psychiatry 1993;44:1145-1149.
54. Beasley CM, Tollefson GD, Tran PV. Efficacy of olanzapine: An overview of pivotal clinical trials. J Clin Psychiatry 1997; 58(Suppl 10):7-12.
55. Yousef HA. A five year follow-up study of chronic schizophrenics and other psychotics treated in the community: Depot haloperidol decanoate versus other neuroleptics. Advances in Therapy 1989;67:186-195.
56. Glazer W, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients. J Clin Psychiatry 1996;57:337-345.
57. Rice DP, Kelman S, Miller LS. The economic burden of mental illness. Hosp Community Psychiatry 1992;43:1227-1232.
58. National Advisory Mental Health Council. Healthcare reform for Americans with severe mental illness. Am J Psychiatry 1993; 150:1447-1465.
59. Somerai SB, Mclaughlin TJ, Ross-Degnan D, et al. Effects of limiting Medicaid drug-reimbursements benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med 1994;331:650-655.
60. Revicki DA, Luce BR, Wechsler JM, et al. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Community Psychiatry 1990;41:850-854.
61. Meltzer HY, Cola P, Way L, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993;150:1630-1638.
62. Reid WH, Mason M, Toprac M. Savings in hospital bed days related to treatment with clozapine. Hosp Community Psychiatry 1994;45:261-264.
63. Rosenheck R, Cramer J, Weichun X, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997;337: 809-815
64. Lindstrom E, Eriksson B, Hellgren A, et al. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 1995;17;402-412.
65. Addington DE, Jones B, Bloom D, et al. Reduction in hospital days in chronic schizophrenic patients treated with risperidone: A retrospective study. Clin Ther 1993;15:917-926.
66. Albright PS, Livingstone S, Keegan DL et al. Reduction of Healthcare resource utilization and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: A retrospective analysis using the Saskatchewan Health linkable databases. Clin Drug Invest 1996;11:289-299.
67. Viale G, Mechling L, Maislin G, et al. Impact of risperidone on the use of mental healthcare resources. Psychiatric Services 1997;48;1153-1159.